Safety and Immunogenicity of Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster
- Summary
- A phase Ⅱ, observer-blind, randomized, controlled, investigator-initiated clinical trial to evaluate the safety and immunogenicity of a booster vaccination with Recombinant COVID-19 vaccine (Sf9 Cell) in a population aged 18 years and above who have completed homologous primary vaccination with either Inactivated or mRNA or Viral Vector COVID-19 vaccines at least 6 months prior to enrolment.
- Short title
- Safety and Immunogenicity of Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster
- Official title
- Safety and Immunogenicity of Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster Following Primary Vaccination of Either Inactivated or mRNA or Viral Vector COVID-19 Vaccines
- Control arm
- Active comparator
- Registry reports results
- Listing at source
- Listed
- Recruitment status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Completion date
- 2024-01-26
- First posted
- 2022-07-19
- Registry last updated
- 2024-04-24
- Primary completion date
- 2022-08-18
- Start date
- 2022-07-11
- Actual participants
- Participants
- Participant count basis
- Actual
- Protocol amendments
- Randomisation ratio
- Number of sites
- Registry sponsor category
- Industry
- Lead sponsor
- WestVac Biopharma Co., Ltd.
- Source registry
- ClinicalTrials.gov
- Registry ID
- NCT05463354
- ClinicalTrials.gov ID
- NCT05463354
- Registry record
- Open registry record
- Allocation
- Randomised
- Model
- Parallel groups
- Purpose
- Prevention
- Masking
- Triple masking
- Masked roles
- Participants, Investigators, Outcome assessors
Incidence of adverse drug reactions (ADRs)
Timeframe: Day 0-28 post-boost dose.
Geometric mean titer (GMT) of specific neutralizing antibody (Virus or Pseudovirus Neutralization Assay) against SARS-CoV-2
Timeframe: Day 14 post-boost dose.
Seroconversion rate (≥ 4 folds increase from baseline) of serum anti-SARS-CoV-2 neutralizing antibody titers
Timeframe: Day 14 post-boost dose.
Incidence of adverse events (AEs)
Timeframe: Day 0-7 post-boost dose
Incidence of AEs
Timeframe: Day 0-28 post-boost dose
Incidence of serious adverse events (SAEs)
Timeframe: Day 0 through 6 months post-boost dose
The percentage of participants with abnormal hematology, chemistry and urinalysis laboratory values
Timeframe: Day 3 post-boost dose
The percentage of participants with grading shifts in hematology, chemistry and urinalysis laboratory assessments between baseline and 3 days after the booster dose.
Timeframe: Day 3 post-boost dose
GMT of specific neutralizing antibody (Virus or Pseudovirus Neutralization Assay) against SARS-CoV-2
Timeframe: Day 28, month 3 and month 6 post-boost dose
Geometric mean increase (GMI) of specific neutralizing antibody (Virus or Pseudovirus Neutralization Assay) against SARS-CoV-2
Timeframe: Day 14, day 28, month 3 and month 6 post-boost dose
GMT and GMI of IgG antibodies against SARS-CoV-2 S protein RBD
Timeframe: Day 14, day 28, month 3 and month 6 post-boost dose
- Sex
- All
- Age groups
- Adults, Older adults
- Minimum age
- 18 Years
- Maximum age
- 85 Years
- Healthy volunteers
- Yes
- 1. Participant is willing and able to give written informed consent for participation in the trial.
- 2. Male or Female, aged 18 years or above and in good health as determined by a trial clinician.
- 3. Female participants of childbearing potential must be willing to ensure that they or their partner use effective contraception from 1 month prior to first immunisation continuously until 3 months after boost immunisation. See Section "Contraception and Pregnancy" for definition of child-bearing potential and definition of effective contraception.
- 4. In the Investigator's opinion, is able and willing to comply with all trial requirements.
- 5. Willing to allow investigators to discuss the volunteer's medical history with their General Practitioner and access all medical records when relevant to study procedures.
- 6. Agreement to refrain from blood donation during the study.
- 7. Participants who have completed homologous primary vaccination with either Inactivated or mRNA or Viral Vector COVID-19 vaccines (full approval, CMA or EUA) and is at least 6 months post second vaccination.
- 1. Receipt of any vaccine (licensed or investigational) other than the study intervention within 30 days before and after each study vaccination (one week for licensed seasonal influenza vaccine or pneumococcal vaccine)
- 2. Prior or planned receipt of any other investigational or licensed vaccine or product likely to impact on interpretation of the trial data (e.g. adenovirus vectored vaccines, any coronavirus vaccines)
- 3. Positive SARS-CoV-2 RT-PCR at screening.
- 4. Participants who are pregnant at enrolment or planning to become pregnant during the first 3 months following vaccination.
- 5. Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccines.
- 6. Any confirmed or suspected immunosuppressive or immunodeficient state; asplenia; recurrent severe infections and use of immunosuppressant medication within the past 6 months, except topical steroids or short-term oral steroids (course lasting ≤14 days).
- 7. History of allergic disease or reactions likely to be exacerbated by any component of study vaccines.
- 8. Any history of anaphylaxis.
- 9. Current diagnosis of or treatment for cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ).
- Iloilo Doctors HospitalIloilo City, Philippines
Related records
Drugs (1)
Lead sponsors (1)
Conditions (1)
- COVID-19 Primary condition